Allison Luo

Allison Luo, MD is the Chief Medical Officer of Mirador Therapeutics, a San Diego precision-medicine company that launched in 2024 with more than $400 million to attack immuno-fibrotic diseases using its Mirador360 development engine. A physician scientist with more than two decades in clinical development, she was CMO of Prometheus Biosciences before Merck bought it for $10.8 billion, and has since reassembled with that team to build Mirador. She sits on the board of Triveni Bio and has held medical-leadership roles across Ventyx, Biora, Iveric Bio and Bristol Myers Squibb.